Aligned Genetics Inc

Aligned Genetics Inc has a market capitalization of 58,974,459,430 KRW and a price-to-earnings ratio of 20.26, indicating a moderate valuation relative to its earnings. The company's price-to-book ratio is 1.59, suggesting that the market values the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 5.08, indicating strong short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which may pose a liquidity risk. In terms of profitability, Aligned Genetics Inc has a return on equity of 7.83% and a return on assets of 5.04%, which are below the industry median for the Advanced Medical Equipment & Technology sector. The company's operating margin is 15.43% (calculated as operating income of 2,471,798,510 KRW divided by revenue of 16,015,916,140 KRW), which is also below the industry median. The company's gross margin is 69.99% (calculated as gross profit of 11,227,223,170 KRW divided by revenue of 16,015,916,140 KRW), which is above the industry median. Aligned Genetics Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company's geographic exposure is primarily in South Korea, with no significant international operations disclosed. The company's revenue concentration in a single segment and geographic region may increase its exposure to sector-specific and regional economic risks. The company's revenue growth trajectory is not explicitly provided in the latest financial data, but the company's free cash flow is negative at -9,380,563,530 KRW, indicating that the company is not generating sufficient cash from operations to cover its capital expenditures. The company's capital expenditures are significant at -12,905,954,920 KRW, which may indicate ongoing investment in its operations. The company's operating cash flow is 3,605,156,900 KRW, which is positive but not sufficient to cover its capital expenditures. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.39, which is relatively low, indicating a conservative capital structure. However, the company's negative net cash position after subtracting total debt may pose a liquidity risk. The company has not disclosed any recent events or filings that would significantly impact its risk profile. The company's recent financial data does not include specific events or filings that would significantly impact its operations or financial position. The company's financial statements do not disclose any recent acquisitions, divestitures, or significant changes in its business strategy. The company's financial performance is primarily driven by its core operations in the medical equipment sector.